HomeEverything
Equities & FundsCrypto & Digital AssetsAI & TechnologyBusiness & CorporateUS Politics & PolicyGeopolitics & Global RiskMacro, Rates & FXCommodities & EnergyEuropean Politics & MarketsAsia-PacificReal Estate & Property
← All Stories

FDA allows Philip Morris to market Zyn as less harmful than cigarettes

Created at 30 Jun · 3:39 PM1 source↑ Market-relevant
IN SHORT

The U.S. Food and Drug Administration will permit Philip Morris International to market its Zyn nicotine pouches as posing a lower risk of certain diseases compared to cigarettes. The decision follows a review of scientific evidence presented by the company.

✉Newsletter

PiQ Daily

Pick your topics. Get only what matters, on your cadence.

Key Numbers

20Zyn product variants authorized for marketing
January 2025Zyn received marketing authorization from FDA
$3.24 billionZyn's sales in the past year

Who's Involved

Philip Morris International
Company seeking marketing authorization for Zyn nicotine pouches
U.S. Food and Drug Administration (FDA)
Regulator reviewing Zyn's marketing claims
Keagan Lenihan
Chief External Affairs Officer for PMI U.S.
Swedish Match USA Inc.
PMI-affiliate that applied for MRTP designation
FDA allows Philip Morris to market Zyn as less harmful than cigarettes

↳ Why This Matters

This FDA decision allows Philip Morris International to actively market Zyn as a reduced-risk alternative to cigarettes, potentially influencing consumer choices and the broader tobacco market landscape. It signifies a regulatory acknowledgment of certain nicotine products as potentially less harmful than traditional combustible cigarettes.

Key facts

  • The FDA will allow Philip Morris International to market Zyn nicotine pouches as less harmful than cigarettes.
  • The marketing claim states that using Zyn instead of cigarettes lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.
  • This authorization applies to 20 variants of Zyn products.
  • Zyn is the fastest-growing nicotine product in the U.S.
  • Zyn received marketing authorization from the FDA in January 2025.

The U.S. Food and Drug Administration (FDA) has authorized Philip Morris International (PMI) to market its Zyn nicotine pouches with claims that they pose a lower risk of certain diseases compared to cigarettes. This decision, reported by Reuters and Axios, allows PMI to state that using Zyn instead of cigarettes reduces the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis for 20 variants of the product.

Zyn, a popular nicotine pouch product inserted under the lip, is the fastest-growing nicotine product in the U.S. The FDA's review process involved scientific evidence presented by PMI to its Tobacco Products Scientific Advisory Committee (TPSAC). In a preliminary review, FDA scientists indicated that the proposed modified risk claim appears to be scientifically accurate. They also noted that youth use of nicotine pouches is currently low and that viewing the claim did not increase intentions to use Zyn among young adults.

Philip Morris International's U.S. family of businesses had sought a Modified Risk Tobacco Product (MRTP) designation. The company presented data suggesting ZYN contains substantially lower levels of harmful chemicals than cigarettes and promotes complete switching from combustible products. The FDA had previously granted Zyn marketing authorization in January 2025 through the Premarket Tobacco Product Authorization (PMTA) pathway, making it the first nicotine pouch to receive such approval. Data presented also indicated that consumers understood ZYN products are not entirely risk-free but carry significantly lower risks than continuing to smoke cigarettes.

Frequently asked questions

Zyn is a brand of nicotine pouches that users place under their lip to receive a nicotine buzz. It is considered the fastest-growing nicotine product in the U.S.

Philip Morris can now market Zyn as posing a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis compared to cigarettes.

Yes, Zyn received marketing authorization from the FDA in January 2025 through the Premarket Tobacco Product Authorization (PMTA) pathway.

No, while the FDA acknowledges they may be less harmful than cigarettes, consumers understand that Zyn products are not entirely risk-free.

What Happens Next

01Philip Morris International will begin marketing Zyn with reduced-risk claims.
02The FDA will continue to monitor Zyn usage and its impact on public health.

Get the newsletter.

Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

Cadence

How It Developed

Philip Morris International presented scientific evidence to the FDA's Tobacco Products Scientific Advisory Committee for Zyn nicotine pouches.
The FDA's preliminary review suggested the proposed modified risk claim for Zyn is scientifically accurate.
The FDA stated that youth nicotine pouch use prevalence is currently relatively low.
The FDA stated that among young adults, viewing the proposed claim did not increase intentions to use Zyn.
The FDA will allow Philip Morris to market 20 variants of Zyn products with claims of lower risk for mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis compared to cig
Zyn became the first nicotine pouch product authorized for marketing by the FDA in January 2025.

Sources

T1
Philip Morris says FDA allows marketing Zyn as less harmful than cigarettesReuters
T2
Philip Morris International Urges FDA Advisory Committee to Recommend ...pmi.com
T2
FDA Weighs Allowing Zyn Pouches to Be Marketed as Lower-Risk Nicotine ...usnews.com

Related Stories

Meta loses bid to dismiss US states' claims that Facebook, Instagram addict children
30 Jun · 1:01 PM
SEC seeks public input on regulating prediction market ETFs
30 Jun · 2:27 PM
Switzerland to ease car, medical device standards recognition for US trade deal
30 Jun · 6:26 AM
Trump suspends Morocco phosphate duties for 8 months
30 Jun · 12:39 AM
White House awarded $500M no-bid contract for East Wing ballroom
30 Jun · 10:16 AM